A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

计划入组 250 人 · 首次发布于 2025 年 6 月 10 日

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

计划入组 90 人 · 首次发布于 2026 年 6 月 16 日

A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns

计划入组 6 人 · 首次发布于 2025 年 2 月 7 日

CX13-608

OSU-CG12

NMT-cP12

Corxel's Oral GLP-1 Agonist CX11 Achieves Up to 11.5% Weight Loss in U.S. Phase 2 Obesity Trial

Corxel Pharmaceuticals Acquires Oral GLP-1 Agonist CX11 for Obesity and Diabetes

FDA Clears Corxel's Phase II Trial for Oral GLP-1 Receptor Agonist CX11 in Obesity Treatment